Monte Rosa Therapeutics (GLUE) Share-based Compensation (2020 - 2026)

Monte Rosa Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $49.4 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 832.43% year-over-year to $49.4 million; the TTM figure through Mar 2026 stood at $49.4 million (up 166.29% YoY), while the FY2025 annual figure was $24.2 million, up 4.31% from the prior year.
• Share-based Compensation for Q1 2026 stood at $49.4 million, up from $4.3 million in the prior quarter.
• The five-year high for Share-based Compensation was $49.4 million in Q1 2026, with the low at $100000.0 in Q2 2023.
• The 5-year median for Share-based Compensation is $4.4 million (2025), against an average of $9.9 million.
• Peak annual rise in Share-based Compensation reached 16450.0% in 2023, while the deepest fall reached 99.72% in 2023.
• Monte Rosa Therapeutics' Share-based Compensation stood at $3.3 million in 2022, then climbed by 22.49% to $4.1 million in 2023, then advanced by 9.7% to $4.5 million in 2024, then retreated by 3.58% to $4.3 million in 2025, then surged by 1046.44% to $49.4 million in 2026.
• Business Quant data shows GLUE's Share-based Compensation at $49.4 million in Q1 2026, $4.3 million in Q4 2025, and $4.4 million in Q3 2025.